Gene Therapy with Serum Amyloid P Component Ameliorates Lupus Nephritis in Mice
Author Information
Author(s): Zhang Weijuan, Wu Jin, Qiao Bin, Xu Wei, Xiong Sidong
Primary Institution: Institute for Immunobiology and Department of Immunology, Shanghai Medical College, Fudan University
Hypothesis
Can serum amyloid P component (SAP) treatment alleviate lupus nephritis in mice?
Conclusion
SAP administration effectively alleviated lupus nephritis by modulating anti-dsDNA antibody production and inflammation.
Supporting Evidence
- Treatment with SAP reduced levels of anti-dsDNA antibodies in lupus mice.
- Administration of SAP decreased immune complex deposition in the kidneys.
- Early SAP treatment reversed lupus nephritis symptoms in mice.
- Late SAP treatment alleviated inflammation and proteinuria in established lupus nephritis.
Takeaway
Researchers found that a treatment called SAP can help sick mice with a disease similar to lupus feel better by reducing harmful antibodies and inflammation.
Methodology
BALB/c mice were treated with a plasmid encoding SAP and assessed for changes in lupus nephritis symptoms and immune responses.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
6- to 8-week-old female BALB/c mice
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website